Table 2.

Key questions used to develop the guideline

1	Who are the targeted people for these guidelines?
2	What are the fracture risk factors?
3	How to assess for fracture risk and what are the cut-off points?
4	How is osteoporosis diagnosed?
5	When osteoporosis is diagnosed, what is the approach for an appropriate evaluation?
6	What are the fundamental non-pharmacologic measures recommended for optimum bone health?
7	Who is in need for pharmacologic therapy?
8	What medication should be used to treat osteoporosis?
9	What is the approach for osteoporosis pharmacological management?
10	What are the recommendations for calcium and vitamin D supplement therapy?
11	How is treatment monitored?
12	Treat-to-target: What are the targets that reflect successful osteoporosis management?
13	How long should patients be treated?
14	Is there an opportunity for a drug holiday?
15	What is the role of concomitant use of therapeutic agents?
16	What is the role of sequential use of therapeutic agents?
17	What is the role of vertebral augmentation for compression fractures?
18	What is the importance of falls assessment?
19	How important is the implementation of fracture liaison service (FLS)?
20	How osteoporosis in men is managed?
21	How to manage the patients on glucocorticoids therapy?
22	What is the advice given to osteoporosis patients during the COVID-19 pandemic?